Recalcitrant infectious uveoscleritis: A case report of a coinfection by Epstein-Barr virus and Talaromyces marneffei

Sukhum Silpa-archa a,*, Nitchamon Rangseechamrat a, Wararee Sriyuttagrai b

a Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand
b School of Medicine, Walailak University, Bangkok, Thailand

1. Introduction

With regard to uveitis, EBV has been found in inflamed eyes of patients with and without HIV infection. There has been controversy regarding EBV’s pathogenic role and the need to treat it. A number of uveitis patients with proven EBV DNA have reported clinical improvement with systemic acyclovir therapy, the most commonly used treatment for EBV-associated uveitis, with or without intravitreal injection [1–3]. Besides acyclovir, nucleoside analogs with antiviral activity, such as ganciclovir and famciclovir, have shown moderate potency in suppressing virus replication during active diseases featured by acute or lytic replication of EBV [4–6]. However, amid the controversy regarding the role of systemic acyclovir [7], there has been sparse reporting of intravenous ganciclovir treatment for EBV-associated uveitis. Talaromyces marneffei infection has long been linked to acquired immunodeficiency syndrome, which is caused by HIV infection. It can induce infectious keratitis and uveitis in the eye [8], but endophthalmitis is rare [9]. However, no case of EBV and Talaromyces marneffei coinfection in an immunocompromised patient has been reported. Thus, we report a rare case of HIV infection with sclerouveitis caused by EBV and Talaromyces marneffei, which was successfully treated with a combination of ganciclovir and amphotericin B. This case report has been reported in line with the SCARE Criteria [10].

2. Case presentation

A 47-year-old HIV-positive female with a history of treated pulmonary tuberculosis presented, complaining of experiencing painful blurry vision in her left eye for 2 weeks. She had been treated with efavirenz, lamivudine, and tenofovir, and her CD4 count was 25 cells/mm³. Visual acuity of her right eye was no light perception for 2 months after she developed cytomegalovirus retinitis with rhegmatogenous retinal detachment in the right eye, and she refused curative surgery. At presentation, her best-corrected visual acuity (BCVA) in the left eye had decreased from 20/20 in the previous few months to 20/100. In the left eye, slit-lamp examination showed a whitish scleral nodule of 2.5 × 4.5 mm from 3 to 5 o’clock with dilated superficial episcleral vessels (Fig. 1A). There were 3+ anterior chamber cells and a vascularized...
tumor at the iris base from 3 to 5 o’clock. The vascularized tumor was covered with white plaque around 1.2 × 1.1 mm in size at the inferotemporal iris. The view of fundus of the left eye was hazy, however, with a flat retina. B-scan ultrasonography of the left eye demonstrated no vitritis. Presumptive diagnosis of infectious sclerouveitis was made, and laboratory workup was conducted. Treatment commenced with oral ciprofloxacin 500 mg twice a day and moxifloxacin 0.5% eye drops (every 2 h) followed by 1% prednisolone acetate eye drops (every hour).

Ten days later, visual acuity of her left eye dropped to counting fingers at 1 foot due to a cloudier cornea and 4+ anterior chamber cells with plasmoid aqueous. Her complete blood count showed mild microcytic hypochromic anemia and leukopenia while syphilis testing, toxoplasma serology, chest radiograph, and urine analysis were unremarkable. Aqueous humor was obtained and analyzed using the multiplex real-time PCR technique to detect viral pathogens (herpes virus family, adenovirus, human parechovirus, human enterovirus, mumps virus, and parvovirus B19) and real-time PCR was also used to identify Mycobacterium tuberculosis (MTB) complex genome. A few days after she had been hospitalized, the PCR result was positive only for EBV. As a result, she was diagnosed with EBV-associated sclerouveitis and received a 2-week course of 5 mg/kg intravenous ganciclovir twice daily with adjunctive intravitreal ganciclovir injections twice a week. During the first week of therapy, her condition remained stable, and an experienced uveitis specialist (S.S.) performed an incisional scleral biopsy. The pathological result showed granulomatous inflammation with negative staining for acid-fast bacilli (AFB), mucin, Gomori’s methamine silver (GMS), Periodic-Acid-Schiff (PAS), Haematoxylin and eosin (H & E), and Epstein-Barr encoding region (EBER) in situ hybridization. However, scleral tissue analysis with PCR was positive for EBV but negative for MTB. The results of comprehensive microbiological study including gram staining, potassium hydroxide (KOH) preparation, acid-fast staining, mycobacterial cultures, and fungal cultures, were negative. As such, diagnosis of EBV-associated sclerouveitis was confirmed. During the second week of intravenous ganciclovir therapy with adjunctive treatment of 2% ganciclovir eye drops (4 times/day) and 1% prednisolone acetate eye drops (8 times/day) to the left eye, her condition improved continuously (Fig. 1B). Ten days after the scleral biopsy, her left eye BCVA had improved to 20/63, and she was discharged with eye drops of ganciclovir, moxifloxacin, and prednisolone acetate.

One week after discharge, the scleral nodule on the inferotemporal side of the sclera increased in size, while the vascularized tumor had not relapsed (Fig. 1C); therefore, topical prednisolone acetate was decreased to four times daily, and ganciclovir eye drops were increased to one drop every 2 hours in the left eye. The regimen did not improve her condition, and iris neovascularization was present at 1-week follow-up. Rescue treatment, including intralesional and intracameral ganciclovir injection together with intravitreal bevacizumab, was employed. After 2 weeks of the rescue treatment, iris plaque had relapsed and leukoplakic papillae was observed while scleral lesion was stabilized by the treatment combination of ganciclovir, moxifloxacin, and prednisolone acetate eye drops.

She was hospitalized for the second operation including phacoemulsification without intraocular lens implantation, and sclerouveal tissue biopsy in the left eye performed by an experienced uveitis specialist (S.S.). Intraoperatively, an oval window of exposed uveal tissue was observed after diseased sclera was removed (Fig. 1D), while the retina appeared normal. Sclerouveal tissue section stained with GMS and PAS demonstrated a yeast form organism with binary fission, which was morphologically compatible with Talaromyces marneffei (Fig. 2). PCR analysis showed that aqueous specimen was still positive for EBV; thus, diagnosis of EBV/fungus coinfected sclerouveitis in the left eye was confirmed. As recommended by infectious disease specialists, a 2-week course of intravenous amphotericin B in combination with intracameral amphotericin B injection was employed. Ten days after the treatment, a significant regression of iris plaque was observed, and exposed uveal tissue appeared healthy without recurrence of scleritis. Although a surgical option for scleral exploration with scleral patch graft was offered, the patient refused to proceed to surgery. Her BCVA was...
hand movement due to cloudy cornea and aphakic condition. After the completion of intravenous amphotericin B, she was discharged from the hospital and lost to follow-up.

3. Discussion

The pathogenicity of EBV for uveitis is controversial for two reasons: 1) the difficulty in differentiating EBV latent infection from active lytic infection; and 2) the majority of EBV-associated intraocular inflammation co-exists with other pathogens which are more likely than EBV to be the culprits [11,12]. In our case, EBV was proven to be the only culprit by PCR analysis of the aqueous humor before Talaromyces marneffei was later identified by pathological analysis. Acyclovir is the most commonly used antiviral treatment for EBV-associated uveitis; [1–3] however, its effectiveness for EBV-associated disease is still uncertain [7]. The beneficial role of ganciclovir therapy has been proven by an association with low or undetectable EBV DNA load [13], and there has been sparse reporting of the efficacy of ganciclovir treatment for EBV-associated uveitis. Our combination of systemic and local ganciclovir therapy appeared to cause the regression of scleral nodule and iris plaque.

Unfortunately, with her immune deficiency status, she later developed recurrent scleral nodule. The same extensive infectious workup including pathological investigation was conducted, and it was found that she was coinfected with Talaromyces marneffei. Although former pathological analysis failed to detect Talaromyces marneffei, we believe that such organism may be present at the beginning. Shi and coworkers recently reported a similar case of iris tumor secondary to Talaromyces marneffei infection in a patient with AIDS. Next-generation sequencing identified Talaromyces marneffei, and the PCR of fungus 26s rDNA was positive in the aqueous humor [14]. The patient’s iris tumor and cutaneous lesions had subsided completely due to the combination therapy of oral voriconazole and fluconazole eye drops. Amphotericin B is a first-line agent for the initial treatment of talaromycosis [15]. Previous reports of cases with uveitis secondary to Talaromyces marneffei have also demonstrated good response to the combined treatment, consisting of intravenous amphotericin and intraocular amphotericin injection [8, 16]. In our work, a 2-week course of intravenous amphotericin B in combination with intracameral amphotericin B injection rendered a significant regression of iris plaque. Nevertheless, there was still positive EBV DNA in the aqueous specimen, which was considered to be due to the remnants of dead virus due to the former resolution of the lesions.

In conclusion, a HIV-infected patient with sclerouveitis can be coinfected with EBV and Talaromyces marneffei. Systemic and local ganciclovir therapy were clinically effective for the treatment of EBV, while amphotericin B was the preferred treatment for Talaromyces marneffei.

Sources of funding 

SS received fund from Rajavithi research funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Ethical approval

The study followed the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of Rajavithi Hospital (approval No. 249/2564).

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author contribution

Sukhum Silpa-archa conceived the study, participated in design and coordination, data interpretation, drafted and edited the article. Sukhum Silpa-archa, Nitchamon Rangseechamrat and Wararee Sriyuttagrai participated in coordination and data collection. Sukhum Silpa-archa edited the article. All authors read and approved the final version of the article.

Research registration

Not applicable.

Guarantor

Sukhum Silpa-archa.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Declaration of competing interest

None.

Acknowledgements

The authors thank Dr. Teerasit Viyanant for excellent pathological assistance, and Mr. John Flanagan for English editing.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2022.104283.
References

[1] E.W. Chan, V. Sun, M. Eldeeb, M.A. Kapusta, Epstein-barr virus acute retinal necrosis in an immunocompetent host, Retin. Cases Brief Rep. (Oct 23 2018), https://doi.org/10.1097/ICB.0000000000000819.

[2] C. Oe, M. Hirakawa, S. Tanaka, H. Ohguro, Acute retinal necrosis associated with Epstein-Barr virus in a patient undergoing immunosuppressive therapy, Case Rep. Ophthalmol. 7 (1) (2016) 195–201, https://doi.org/10.1159/000445372.

[3] D.A. Bustos-Mejia, R. Parra-Medina, A. de-la-Torre, Nodular nectrotizing-scleritis associated with Epstein-Barr virus infection: a case report, Ocul. Immunol. Inflamm. 29 (4) (2020) 556–558, https://doi.org/10.1080/09273948.2019.1611877.

[4] J.R. Kerr, Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors, J. Clin. Pathol. 72 (10) (2019) 651–658, https://doi.org/10.1111/j.1365-2788.2019.12983.x.

[5] G. Andrei, E. Trompet, R. Snoeck, Novel therapeutics for Epstein(-)Barr virus, Molecules 24 (5) (2019), https://doi.org/10.3390/molecules24050997.

[6] S. Silpa-Archa, W. Sriyuttagrai, C.S. Foster, Treatment for Epstein-Barr Virus-associated uveitis confirmed by polymerase chain reaction: efficacy of Anti-Viral Agents and a literature review, J. Clin. Virol. 147 (2022), 105079, https://doi.org/10.1016/j.jcv.2022.105079.

[7] M. De Paor, K. O’Brien, T. Fahey, S.M. Smith, Antiviral agents for infectious mononucleosis (glandular fever), Cochrane Database Syst. Rev. 12 (2016) CD0011487, https://doi.org/10.1002/14651858.CD0011487.pub2.

[8] C. Khieu, A. Apivatthakakul, P. Kunavisarut, K. Pathanapitoon, Case report: bilateral granulomatous anterior uveitis in HIV-patient with disseminated talarmycosis (penicilliosis) marneffei infection, Ocul. Immunol. Inflamm. 28 (7) (2020) 1066–1068, https://doi.org/10.1080/09273948.2019.1657468.

[9] K. Kanda, K. Takayama, T. Enoki, M. Takeuchi, Chronic postcataract endophthalmitis caused by Penicillium species in an immunocompetent patient, Int. Med. Case Rep. J. 11 (2018) 259–262, https://doi.org/10.2147/IMCRJ.S175834.

[10] R.A. Agha, T. Franchi, C. Sohrabi, G. Mathew, A. Kerwan, S. Group, The SCARE 2020 guideline: updating consensus surgical Case REport (SCARE) guidelines, Int. J. Surg.. 84 (Dec 2020), 226-230 doi:10.1016/j.ijsu.2020.10.034.

[11] T. Sato, R. Kitamura, T. Kaburaki, M. Takeuchi, Retinitis associated with double infection of Epstein-Barr virus and varicella-zoster virus: a case report, Medicine (Baltim.) 97 (31) (Aug 2018), e11663, https://doi.org/10.1097/MD.0000000000011663.

[12] D. Smit, D. Meyer, J. Marin, J.D.F. de Groot-Mijnes, Polymerase chain reaction and Goldmann-Witmer coefficient to examine the role of Epstein-Barr virus in uveitis, Ocul. Immunol. Inflamm. 27 (1) (2019) 108–113, https://doi.org/10.1080/09273948.2017.1379653.

[13] S. Bosmalaco, K.I. Falk, M. Ponazoni, N. Cesarini, F. Crippa, A. Lazzarin, A. Linde, P. Cinque, Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma, Clin. Infect. Dis. 42 (4) (2006) e21–25, https://doi.org/10.1086/499956.

[14] T. Shi, L. Wu, J. Cai, H. Chen, An Iris tumor secondary to Talaromyces marneffei infection in a patient with AIDS and syphilis, Ocul. Immunol. Inflamm. (2021) 1–4, https://doi.org/10.1080/09273948.2021.1878234.

[15] T. Le, V.T. Ly, N.T.M. Thu, A. Nguyen, N.T. Thanh, N.V.V. Chau, G. Thwaites, J. Perfect, R. Kolamunnage-Dona, W. Hope, Population pharmacodynamics of amphotericin B deoxycholate for disseminated infection caused by Talaromyces marneffei, Antimicrob. Agents Chemother. 63 (2) (Feb 2019), https://doi.org/10.1128/AAC.01739-18.

[16] F.J. Vilar, R. Hunt, E.G. Wilkins, G. Wilson, N.P. Jones, Disseminated Penicillium marneffei in a patient infected with human immunodeficiency virus, Int. J. STD AIDS 11 (2) (Feb 2000) 126–128, https://doi.org/10.1097/00005646-200011000-00002.